Dr. Jackson T. Wright Jr. honored for reducing heart disease among African Americans
When Jackson T. Wright Jr. MD, PhD, began practicing medicine in the 1980's, physicians knew that the risks of high blood pressure were greater in African Americans compared to Caucasians. But what was not known was the dramatic difference in effective prevention and treatment strategies between the two patient populations. That's because the larger clinical hypertension studies included mostly Caucasians. The few, small studies in African-American populations meant that insufficient evidence was available to base major conclusions on treating hypertensive African-American patients.
The groundbreaking, decades-long clinical research by Wright helped physicians create and fine-tune approaches to address hypertension not only among the general population, but also in understanding and controlling the disease among African-Americans. For this body of work, Wright, who is professor of medicine at Case Western Reserve University School of Medicine as well as the director of the clinical hypertension program and the program director of the W.T. Dahms MD Clinical Research Unit at University Hospitals Case Medical Center, received the American Heart Association's 2015 Clinical Research Prize for outstanding achievement in clinical cardiovascular science.
"Hypertension is the leading cause of death in the world, and it is particularly epidemic within the African American community," Wright says. "Everyone in my family had hypertension, and my blood pressure was on its way up when I started out my medical career, so I had a vested interest in the disease."
Because it disproportionately affects minority populations, Wright was interested in designing clinical trials that investigate how various therapeutic and preventative approaches to cardiovascular disease affect these groups. One area of particular interest is preventing the consequences of ongoing hypertension that leads to a cascade of harmful health effects: heart attack, stroke, congestive heart failure, kidney damage, vision loss, and dementia. Wright's work helped lead to efforts in National Institutes of Health-funded clinical trials that acquired the evidence necessary to base sound treatment and prevention conclusions, not only for African-Americans and Caucasians, but other ethnic populations as well.
Wright's contributions have been instrumental in describing the prevalence of hypertension among African-Americans and developing clinical guidelines to address it. The 1,100-participant, 21-center African-American Study of Kidney Disease in Hypertensives Trial (AASK) reported in 2002 that African-American patients with high blood pressure have up to a 20-fold risk for renal disease requiring dialysis compared to majority populations. The 42,488-participant Antihypertensive and Lipid-Lowering to Prevent Heart Attack Trial (ALLHAT) with more than 15,000 Blacks reported on the ideal antihypertensive drug regimen for preventing cardiovascular and kidney events among various ethnic groups.
The most recently reported 9,361-participant (30% are African American), 102-center Systolic Blood Pressure Intervention Trial (SPRINT) showed that treating patients to a less than 120 mmHg systolic blood pressure produced marked reductions in cardiovascular events and mortality compared to treatment to systolic blood pressures less than 140 mmHg.
Wright also participates in key national decision-making bodies to develop treatment guidelines for hypertension. Currently, he serves on an American Heart Association and American College of Cardiology hypertension guidelines panel.
"There is still much to do," Wright said. "We need to define better treatment for both the prevention and the treatment of hypertension. It would be a strong step forward if we could develop more effective strategies to prevent the development of hypertension rather than simply treating it and its complications."
His peers in hypertension clinical research credit Wright with playing a pivotal role in uncovering how hypertension manifests itself uniquely among different patient populations and how that knowledge could contribute to narrowing the health disparity gaps that negatively affect African-Americans.
"He has been an important driver in enrolling minorities in hypertension clinical trials," said fellow clinical researcher Anne Taylor, MD, the senior vice president for Faculty Affairs and Career Development, the John Lindenbaum Professor of Medicine at Columbia University's College of Physicians and Surgeons, and study chair for the African American Heart Failure Trial. "But, it is about more than just ensuring minority patients are included. It's the outcomes of the trial showing the differences and similarities between populations differing in race or ethnicity. This helps guide us in the medical care of patients in a much more focused, directed and personalized way. It's information that helps with assessment of individual patient risk for disease outcomes, as well as our choice of therapy and monitoring of outcomes of therapy."
Taylor also commends Wright for supporting minorities to pursue careers in academic medicine and clinical research. He has provided significant leadership for the Program on Careers in Academic Medicine of the National Institute of Diabetes and Digestive and Kidney Diseases and the National Medical Association.
"The roles and responsibilities he has been given are a reflection of the esteem in which he is held," said colleague Mahboob Rahman, MD, MS, professor of medicine, Case Western Reserve University School of Medicine, and nephrologist, University Hospitals Case Medical Center and Louis Stokes VA Medical Center. "He holds leadership roles in all the major hypertension studies the NIH has funded in the recent past. That is a reflection of how highly he is regarded."
Another fellow hypertension researcher, William C. Cushman, MD, professor of preventive medicine and medicine at the University of Tennessee Health Science Center, and chief of preventive medicine at the VA Medical Center, concurs: "His advocacy has had a tremendous impact not only in conducting the clinical trials, but also in disseminating that evidence through educating clinicians and getting that information incorporated into clinical guidelines."